Brief: Altamira Therapeutics Files Provisional Patent Application For Oligophore Nanoparticles Targeting Different Kras Mutations In Cancer Treatment
27/02/2023 14:06
Altamira Therapeutics Ltd CYTO.O :
* ALTAMIRA THERAPEUTICS FILES PROVISIONAL PATENT APPLICATION
FOR
OLIGOPHORE NANOPARTICLES TARGETING DIFFERENT KRAS MUTATIONS IN
CANCER TREATMENT
Source text for Eikon: ID:nGNX1php15
Further company coverage: CYTO.O
Recent news on Altamira Therapeutics
See all newsBrief: Altamira Therapeutics Reports Full Year 2024 Results
Brief: Altamira Therapeutics Announces Transition From Nasdaq To OTC Markets
Brief: Altamira Therapeutics Provides Update On Nasdaq Listing
Brief: Altamira Therapeutics Provides Business Update And First Half 2024 Financial Results
Brief: Altamira Therapeutics Announces Pricing Of Up To $12.0 Mln Public Offering